Submucosal Bevacizumab for the Management of Recurrent Epistaxis in Patients With Hereditary Hemorrhagic Telangiectasia (HHT)

NCT01402531 PHASE2 COMPLETED Results posted

This is a research study to find out more about the use of Avastin (proper chemical name is bevacizumab) in the treatment of epistaxis (nose bleeding) in patients with Hereditary Hemorrhagic Telangiectasia (HHT).

Details

Lead sponsor	University of California, San Diego
Phase	PHASE2
Status	COMPLETED
Enrolment	10
Start date	Thu Jul 22 2010 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Sat Jul 27 2013 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Hereditary Hemorrhagic Telangiectasia (HHT)

Interventions

• Submucosal Bevacizumab

Countries

United States